Pipeline Trends: Neuroprotective Compounds
Several of the potentially neuroprotective compounds in the PD pipeline focus on alpha-synuclein, the protein that forms toxic clumps in the brain cells of people with PD. Potential therapies would harness the immune system to clear alpha-synuclein or use vaccines to prevent or halt alpha-synuclein build-up. In addition, a few others — for example, isradipine — have been used for years to treat other health conditions and supplements such as NAC and inosine.
Does anyone have experience with any of these Phase I / II trials?
Phase I:
AAV2-GDNF. A gene therapy treatment designed to boost levels of GDNF, a naturally occurring protein that may protect dopamine neurons in the brain.
BIIB054. An immunotherapy that clears alpha-synuclein, a protein whose build-up is thought to contribute to PD.
NPT200-11. A drug designed to stabilize the brain protein alpha-synuclein, whose misfolding is related to PD.
PRX002. An immunotherapy that clears alpha-synuclein, a protein whose build-up is thought to contribute to PD.
PD: Search for the Holy Grail
Nano-plastics affect a specific protein found in the brain, causing changes linked to Parkinson’s disease and other types of dementia.
Ever wonder about questions that are in the minds of key Parkinson's researchers? Here's a sample . . . .
Short Chain Fatty Acids, sodium butyrate, phenylbutyrate
AS accumulates in the appendix. 
